Leveraging novel science and a differentiated approach, our platform technology provides the opportunity to address a number of serious indications, including chronic cough, neuropathic pain, migraine and hyperactive bladder.
Our lead program, EX937, is a first-in-class, proprietary small molecule being developed for refractory chronic cough, a large underserved market with no current FDA-approved therapies.
News and Press Releases 
